Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Gastroenterology|March 23, 2015
Identification of Extracolonic Pathologies by Computed Tomographic Colonography in Colorectal Cancer Symptomatic PatientsSteve Halligan, Katherine Wooldrage, Edward Dadswell, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 5, 2021
Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapyMarion Eveillard, Neha Korde, Amanda Ciardiello, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 16, 2019
Barriers to Allogeneic Hematopoietic Stem Cell Transplantation for Human T Cell Lymphotropic Virus 1-Associated Adult T Cell Lymphoma-Leukemia in the United States: Experience from a Large Cohort in a Major Tertiary CenterDiego Adrianzen Herrera, Noah Kornblum, Ana Acuna-Villaorduna, et al.
The Lancet. Oncology|May 2, 2017
Adenoma surveillance and colorectal cancer incidence: a retrospective, multicentre, cohort studyWendy Atkin, Kate Wooldrage, Amy Brenner, et al.
Leukemia & Lymphoma|June 18, 2019
High prevalence of pulmonary findings in computed tomographies of HTLV-1-infected patients with and without adult-T cell leukemia/lymphoma - implications for stagingAna Acuna-Villaorduna, Jesus Gonzalez-Lugo, B Hilda Ye, et al.
Health Technology Assessment (Winchester, England)|June 17, 2017
The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluationsWendy Atkin, Amy Brenner, Jessica Martin, et al.
Research Square|March 3, 2023
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple MyelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Blood Cancer Journal|July 25, 2023
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Research Square|February 26, 2024
Comparison of Infectious Complications with BCMA-directed Therapies in Multiple MyelomaAlexander Lesokhin, Karthik Nath, Tala Shekarkhand, et al.
Blood|May 10, 2024
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myelomaRoss S Firestone, Nicholas D Socci, Tala Shekarkhand, et al.
Pageof 4